inpefa drug：Lexicon finally scores FDA nod for heart failure drug Inpefa
Lexicon finally scores FDA nod for heart failure drug Inpefa
2023年5月30日—Aftersetbacks,Lexicon'sSGLT1/SGLT2inhibitorInpefahasgainedanFDAapprovaltoreducetheriskofheartfailure.。其他文章還包含有：「FDAApprovesInpefaasFirstDualHeartFailureMedication」、「INPEFAcancauseserioussideeffects」、「InpefaOral:Uses,SideEffects,Interactions」、「Inpefa」、「Inpefa」、「Inpefa:Uses,Dosage」、「INPEFATM(sotagliflozin)tablets」、「NowApproved」、「Once」
查看更多 離開網站
FDA Approves Inpefa as First Dual Heart Failure Medication
https://diatribe.org
Inpefa (sotagliflozin) was recently approved by the FDA for heart failure. In trial results, sotagliflozin was shown to lower the risk of ...
INPEFA can cause serious side effects
https://dailymed.nlm.nih.gov
INPEFA is a prescription medicine used to reduce the risk of death due to heart problems (cardiovascular death), hospitalization for heart failure, and urgent ...
Inpefa Oral: Uses, Side Effects, Interactions
https://www.webmd.com
Sotagliflozin is used by people with heart failure or by people with type 2 diabetes, kidney disease, and other heart disease risk factors to lower the risk ...
Inpefa
https://www.managedhealthcaree
Inpefa was approved by the FDA on May 26 and is a once-daily oral tablet that reduces the risk of cardiovascular death, hospitalization for ...
Inpefa
https://www.drugs.com
INPEFA is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated to reduce the risk of cardiovascular death, hospitalization for heart ...
Inpefa: Uses, Dosage
https://www.drugs.com
Inpefa is an inhibitor of both sodium-glucose co-transporter type 2 (SGLT2) and type 1 (SGLT1), two proteins responsible for glucose regulation.
INPEFATM (sotagliflozin) tablets
https://www.accessdata.fda.gov
General information about the safe and effective use of INPEFA. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.
Now Approved
https://www.inpefahcp.com
INPEFA™ is an inhibitor of SGLT2 and SGLT1 for patients with heart failure or patients with comorbidities and other cardiovascular risk factors.
Once
https://www.uspharmacist.com
Inpefa is classified as a dual inhibitor of both sodium-glucose cotransporter type 2 (SGLT2) and type 1 (SGLT1). Inhibiting SGLT2 diminishes ...